Norway Immunoassay For Neurological Biomarkers Market Size & Outlook
Related Markets
Norway immunoassay for neurological biomarkers market highlights
- The Norway immunoassay for neurological biomarkers market generated a revenue of USD 23.0 million in 2023 and is expected to reach USD 52.7 million by 2030.
- The Norway market is expected to grow at a CAGR of 12.6% from 2024 to 2030.
- In terms of segment, alzheimer's disease was the largest revenue generating application in 2023.
- Alzheimer's Disease is the most lucrative application segment registering the fastest growth during the forecast period.
Immunoassay for neurological biomarkers market data book summary
| Market revenue in 2023 | USD 23.0 million |
| Market revenue in 2030 | USD 52.7 million |
| Growth rate | 12.6% (CAGR from 2023 to 2030) |
| Largest segment | Alzheimer's disease |
| Fastest growing segment | Alzheimer's Disease |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
| Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
Other key industry trends
- In terms of revenue, Norway accounted for 0.3% of the global immunoassay for neurological biomarkers market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany immunoassay for neurological biomarkers market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 706.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Immunoassay For Neurological Biomarkers Market Scope
Immunoassay For Neurological Biomarkers Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Nimble Therapeutics | View profile | 11-50 | Madison, Wisconsin, United States, North America | https://www.nimbletherapeutics.com/ |
| Sysmex Corp | View profile | 10448 | 1-5-1 Wakinohara-Kaigandori, Chuo-ku, Hyogo Prefecture, Kobe, Japan, 6510073 | http://www.sysmex.co.jp |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Bio-Rad Laboratories Inc | View profile | 8030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | https://www.bio-rad.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Norway immunoassay for neurological biomarkers market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 36.09% in 2023. Horizon Databook has segmented the Norway immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Leading clinical professionals and academic researchers in the field have collaborated on its development, along with important Norwegian and worldwide partners. For instance, in December 2022, the Michael J.
Fox Foundation awarded USD 300,000 in grants and public money to scientist Charalampos Tzoulis as part of the “Biomarkers to Support Therapeutic Trials Program” for R&D of novel biomarkers for Parkinson’s disease.
Furthermore, in March 2021, the Neuro-SysMed Research School (RSTN) was established at NeuroSysMed. The establishment of such educational institutions is expected to create demand for immunoassays for neurological biomarkers for R&D purpose of researchers, thereby driving the market growth.
Reasons to subscribe to Norway immunoassay for neurological biomarkers market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway immunoassay for neurological biomarkers market databook
-
Our clientele includes a mix of immunoassay for neurological biomarkers market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Norway immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway immunoassay for neurological biomarkers market size, by product, 2018-2030 (US$M)
Norway Immunoassay For Neurological Biomarkers Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
